妇科恶性肿瘤免疫治疗中国专家共识（2023年版）

中国抗癌协会肿瘤内分泌专业委员会

doi:10.19401/j.cnki.1007-3639.2023.10.008

您当前的位置：

首页 >

文章列表页 >

妇科恶性肿瘤免疫治疗中国专家共识（2023年版）

指南与共识 | 更新时间：2025-12-31

- 妇科恶性肿瘤免疫治疗中国专家共识（2023年版）
- Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)
- 中国癌症杂志 2023年33卷第10期页码：954-967
- 作者机构：
- 作者简介：
- 基金信息：
  
  重庆市科技局技术创新与应用发展专项(cstc2019jscx-msxmX0106);重庆英才计划“包干制”项目（基础研究与前沿探索类）(cstc2021ycjh-bgzxm0134);重庆市医学科技创新四大中心建设项目-重庆市卵巢癌专病医学研究中心项目
- DOI：10.19401/j.cnki.1007-3639.2023.10.008
  中图分类号： R737.3
- 收稿：2023-06-05，
  
  修回：2023-09-04，
  
  纸质出版：2023-10-30
- 稿件说明：
移动端阅览
中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识（2023年版）[J]. 中国癌症杂志, 2023,33(10):954-967.

of Onco-Endocrinology of Chinese Anti-Cancer Association Society. Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)[J]. China Oncology, 2023, 33(10): 954-967.
中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识（2023年版）[J]. 中国癌症杂志, 2023,33(10):954-967. DOI： 10.19401/j.cnki.1007-3639.2023.10.008.

of Onco-Endocrinology of Chinese Anti-Cancer Association Society. Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)[J]. China Oncology, 2023, 33(10): 954-967. DOI： 10.19401/j.cnki.1007-3639.2023.10.008.

摘要

免疫治疗作为第四大抗肿瘤治疗方法，已在癌症治疗领域取得了突破性进展，其中免疫检查点抑制剂已广泛应用于多种恶性肿瘤的治疗，在妇科恶性肿瘤领域也积累了较多的临床证据和经验。但目前国内外在免疫检查点抑制剂等免疫疗法应用于妇科恶性肿瘤的治疗方面尚缺乏规范。因此，由中国抗癌协会肿瘤内分泌专业委员会牵头，组织多领域专家，以高质量临床研究结果、2023年美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）会议研究结果等为循证医学依据，通过共同讨论及投票，从而形成《妇科恶性肿瘤免疫治疗中国专家共识（2023年版）》。本共识就妇科常见子宫颈癌、子宫内膜癌、卵巢癌及其他恶性肿瘤分类推荐了免疫检查点抑制剂单药或联合化疗、靶向治疗等临床应用方案。总结了肿瘤疫苗、过继性细胞免疫治疗和细胞因子等免疫治疗在妇科恶性肿瘤中的相关研究及应用情况，供国内同行参考，以期进一步规范妇科恶性肿瘤免疫治疗的临床实践。

Abstract

Immunotherapy

as the fourth largest anti-tumor treatment method

has made breakthrough progress in the field of cancer treatment. Checkpoint inhibitors have been widely used in the treatment of various malignant tumors

and a lot of clinical evidence and experience have also been accumulated in the field of gynecological malignant tumors. However

there is still a lack of standardization in the application of immunotherapy such as immune checkpoint inhibitors for the treatment of gynecological malignant tumors. Therefore

led by the Cancer Endocrine Professional Committee of the China Anti-Cancer Association

experts from multiple fields were organized to use high-quality clinical research results as well as the results of the 2023 American Society of Clinical Oncology (ASCO) conference as evidence. Through discussion and voting

the consensus of Chinese experts on immunotherapy for gynecological malignant tumors (2023 version) has been formed. This consensus recommended the clinical application of immune checkpoint inhibitors for the classification of common gynecological cervical cancer

endometrial cancer

ovarian cancer and other malignant tumors

such as single drug or combination chemotherapy

targeted therapy

etc. It summarized the research and application of tumor vaccines

adoptive cell immunotherapy and cytokine immunotherapy in gynecological malignant tumors

and provided reference for domestic peers

in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors.

关键词

Keywords

references

MCNUTT M . Cancer immunotherapy [J ] . Science , 2013 , 342 ( 6165 ): 1417 . DOI: 10.1126/science.1249481 http://doi.org/10.1126/science.1249481

KIM J Y , KRONBICHLER A , EISENHUT M , et al. Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis [J ] . Cancers , 2019 , 11 ( 11 ): 1798 . DOI: 10.3390/cancers11111798 http://doi.org/10.3390/cancers11111798 https://www.mdpi.com/2072-6694/11/11/1798 https://www.mdpi.com/2072-6694/11/11/1798

SLOAN E A , RING K L , WILLIS B C , et al. PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors [J ] . Am J Surg Pathol , 2017 , 41 ( 3 ): 326 - 333 . DOI: 10.1097/PAS.0000000000000783 http://doi.org/10.1097/PAS.0000000000000783

MARABELLE A , LE D T , ASCIERTO P A , et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study [J ] . J Clin Oncol , 2020 , 38 ( 1 ): 1 - 10 .

MARABELLE A , FAKIH M , LOPEZ J , et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1353 - 1365 . DOI: S1470-2045(20)30445-9 http://doi.org/S1470-2045(20)30445-9

AZAD N S , GRAY R J , OVERMAN M J , et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-a subprotocol of the NCI-MATCH (EAY131) study [J ] . J Clin Oncol , 2020 , 38 ( 3 ): 214 - 222 . DOI: 10.1200/JCO.19.00818 http://doi.org/10.1200/JCO.19.00818

OAKNIN A , TINKER A V , GILBERT L , et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a non-randomized phase 1 clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 11 ): 1766 - 1772 . DOI: 10.1001/jamaoncol.2020.4515 http://doi.org/10.1001/jamaoncol.2020.4515 https://jamanetwork.com/journals/jamaoncology/fullarticle/2771011 https://jamanetwork.com/journals/jamaoncology/fullarticle/2771011

OAKNIN A , POTHURI B , GILBERT L , et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 5509 . DOI: 10.1200/JCO.2022.40.16_suppl.5509 http://doi.org/10.1200/JCO.2022.40.16_suppl.5509 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5509 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5509

KONSTANTINOPOULOS P A , LUO W X , LIU J F , et al. Phase Ⅱ study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer [J ] . J Clin Oncol , 2019 , 37 ( 30 ): 2786 - 2794 . DOI: 10.1200/JCO.19.01021 http://doi.org/10.1200/JCO.19.01021 https://ascopubs.org/doi/10.1200/JCO.19.01021 https://ascopubs.org/doi/10.1200/JCO.19.01021

MAKKER V , COLOMBO N , CASADO HERRÁEZ A , et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer [J ] . N Engl J Med , 2022 , 386 ( 5 ): 437 - 448 . DOI: 10.1056/NEJMoa2108330 http://doi.org/10.1056/NEJMoa2108330 http://www.nejm.org/doi/10.1056/NEJMoa2108330 http://www.nejm.org/doi/10.1056/NEJMoa2108330

ESKANDER R N , SILL M W , BEFFA L , et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer [J ] . N Engl J Med , 2023 , 388 ( 23 ): 2159 - 2170 . DOI: 10.1056/NEJMoa2302312 http://doi.org/10.1056/NEJMoa2302312 http://www.nejm.org/doi/10.1056/NEJMoa2302312 http://www.nejm.org/doi/10.1056/NEJMoa2302312

MIRZA M R , CHASE D M , SLOMOVITZ B M , et al. Dostarlimab for primary advanced or recurrent endometrial cancer [J ] . N Engl J Med , 2023 , 388 ( 23 ): 2145 - 2158 . DOI: 10.1056/NEJMoa2216334 http://doi.org/10.1056/NEJMoa2216334 http://www.nejm.org/doi/10.1056/NEJMoa2216334 http://www.nejm.org/doi/10.1056/NEJMoa2216334

CHUNG H C , ROS W , DELORD J P , et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study [J ] . J Clin Oncol , 2019 , 37 ( 17 ): 1470 - 1478 . DOI: 10.1200/JCO.18.01265 http://doi.org/10.1200/JCO.18.01265 https://ascopubs.org/doi/10.1200/JCO.18.01265 https://ascopubs.org/doi/10.1200/JCO.18.01265

NAUMANN R W , HOLLEBECQUE A , MEYER T , et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial [J ] . J Clin Oncol , 2019 , 37 ( 31 ): 2825 - 2834 . DOI: 10.1200/JCO.19.00739 http://doi.org/10.1200/JCO.19.00739 https://ascopubs.org/doi/10.1200/JCO.19.00739 https://ascopubs.org/doi/10.1200/JCO.19.00739

TEWARI K S , MONK B J , VERGOTE I , et al. Survival with cemiplimab in recurrent cervical cancer [J ] . N Engl J Med , 2022 , 386 ( 6 ): 544 - 555 . DOI: 10.1056/NEJMoa2112187 http://doi.org/10.1056/NEJMoa2112187 http://www.nejm.org/doi/10.1056/NEJMoa2112187 http://www.nejm.org/doi/10.1056/NEJMoa2112187

WU X H , JI J F , LOU H M , et al. Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase Ⅱ trial (075) [J ] . Gynecol Oncol , 2022 , 166 : S47 -S48.

COLOMBO N , DUBOT C , LORUSSO D , et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer [J ] . N Engl J Med , 2021 , 385 ( 20 ): 1856 - 1867 . DOI: 10.1056/NEJMoa2112435 http://doi.org/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435

WANG J , LOU H M , CAI H B , et al. A study of AK104 (an anti-PD-1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC) [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 106 .

LAN C Y , SHEN J X , WANG Y , et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial [J ] . J Clin Oncol , 2020 , 38 ( 34 ): 4095 - 4106 . DOI: 10.1200/JCO.20.01920 http://doi.org/10.1200/JCO.20.01920 https://ascopubs.org/doi/10.1200/JCO.20.01920 https://ascopubs.org/doi/10.1200/JCO.20.01920

XU Q , WANG J J , SUN Y , et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial [J ] . J Clin Oncol , 2022 , 40 ( 16 ): 1795 - 1805 .

MONK B J , COLOMBO N , OZA A M , et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 9 ): 1275 - 1289 . DOI: 10.1016/S1470-2045(21)00342-9 http://doi.org/10.1016/S1470-2045(21)00342-9

MOORE K N , BOOKMAN M , SEHOULI J , et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage Ⅲ or Ⅳ ovarian cancer: placebo-controlled randomized phase Ⅲ trial (IMagyn050/GOG 3015/ENGOT-OV39) [J ] . J Clin Oncol , 2021 , 39 ( 17 ): 1842 - 1855 .

HARTER P , TRILLSCH F , OKAMOTO A , et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA 1/2 mutation (non-t BRCA m): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA5506 . DOI: 10.1200/JCO.2023.41.17_suppl.LBA5506 http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506

CURRAN M A , MONTALVO W , YAGITA H , et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J ] . Proc Natl Acad Sci U S A , 2010 , 107 ( 9 ): 4275 - 4280 . DOI: 10.1073/pnas.0915174107 http://doi.org/10.1073/pnas.0915174107 https://pnas.org/doi/full/10.1073/pnas.0915174107 https://pnas.org/doi/full/10.1073/pnas.0915174107

BOUTROS C , TARHINI A , ROUTIER E , et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J ] . Nat Rev Clin Oncol , 2016 , 13 ( 8 ): 473 - 486 . DOI: 10.1038/nrclinonc.2016.58 http://doi.org/10.1038/nrclinonc.2016.58

CHALABI M , FANCHI L F , DIJKSTRA K K , et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J ] . Nat Med , 2020 , 26 ( 4 ): 566 - 576 . DOI: 10.1038/s41591-020-0805-8 http://doi.org/10.1038/s41591-020-0805-8

O'MALLEY D M , NEFFA M , MONK B J , et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase Ⅱ study [J ] . J Clin Oncol , 2022 , 40 ( 7 ): 762 - 771 . DOI: 10.1200/JCO.21.02067 http://doi.org/10.1200/JCO.21.02067 https://ascopubs.org/doi/10.1200/JCO.21.02067 https://ascopubs.org/doi/10.1200/JCO.21.02067

RODIG S J , GUSENLEITNER D , JACKSON D G , et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma [J ] . Sci Transl Med , 2018 , 10 ( 450 ): eaar3342 . DOI: 10.1126/scitranslmed.aar3342 http://doi.org/10.1126/scitranslmed.aar3342 https://www.science.org/doi/10.1126/scitranslmed.aar3342 https://www.science.org/doi/10.1126/scitranslmed.aar3342

BLANK C U , ROZEMAN E A , FANCHI L F , et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage Ⅲ melanoma [J ] . Nat Med , 2018 , 24 ( 11 ): 1655 - 1661 . DOI: 10.1038/s41591-018-0198-0 http://doi.org/10.1038/s41591-018-0198-0

ZAMARIN D , BURGER R A , SILL M W , et al. Randomized phase Ⅱ trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study [J ] . J Clin Oncol , 2020 , 38 ( 16 ): 1814 - 1823 . DOI: 10.1200/JCO.19.02059 http://doi.org/10.1200/JCO.19.02059 https://ascopubs.org/doi/10.1200/JCO.19.02059 https://ascopubs.org/doi/10.1200/JCO.19.02059

PEDERSEN M , WESTERGAARD M C W , MILNE K , et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study [J ] . Oncoimmunology , 2018 , 7 ( 12 ): e1502905 . DOI: 10.1080/2162402X.2018.1502905 http://doi.org/10.1080/2162402X.2018.1502905 https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1502905 https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1502905

CHENG H Y , MA R Q , WANG S , et al. Preliminary safety and potential effect of 6B11-OCIK adoptive cell therapy against platinum-resistant recurrent or refractory ovarian cancer [J ] . Front Immunol , 2021 , 12 : 707468 . DOI: 10.3389/fimmu.2021.707468 http://doi.org/10.3389/fimmu.2021.707468 https://www.frontiersin.org/articles/10.3389/fimmu.2021.707468/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.707468/full

ROB L , CIBULA D , KNAPP P , et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial [J ] . J Immunother Cancer , 2022 , 10 ( 1 ): e003190 . DOI: 10.1136/jitc-2021-003190 http://doi.org/10.1136/jitc-2021-003190 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003190 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003190

CIBULA D , ROB L , MALLMANN P , et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial [J ] . Gynecol Oncol , 2021 , 162 ( 3 ): 652 - 660 . DOI: 10.1016/j.ygyno.2021.07.003 http://doi.org/10.1016/j.ygyno.2021.07.003

SHAPIRA-FROMMER R , MILESHKIN L , MANZYUK L , et al. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study [J ] . Gynecol Oncol , 2022 , 166 ( 2 ): 211 - 218 . DOI: 10.1016/j.ygyno.2022.01.029 http://doi.org/10.1016/j.ygyno.2022.01.029 https://linkinghub.elsevier.com/retrieve/pii/S0090825822000671 https://linkinghub.elsevier.com/retrieve/pii/S0090825822000671

OAKNIN A , MOORE K N , MEYER T , et al. 520 MO safety and efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer in checkmate 358 [J ] . Ann Oncol , 2022 , 33 ( suppl_7 ): S782 . DOI: 10.1016/j.annonc.2022.07.648 http://doi.org/10.1016/j.annonc.2022.07.648 https://linkinghub.elsevier.com/retrieve/pii/S0923753422024991 https://linkinghub.elsevier.com/retrieve/pii/S0923753422024991

WANG H Y , WU X Y , ZHANG X , et al. Prevalence of NRAS mutation, PD-L1 expression and amplification, and overall survival analysis in 36 primary vaginal melanomas [J ] . Oncologist , 2020 , 25 ( 2 ): e291 -e301. DOI: 10.1634/theoncologist.2019-0148 http://doi.org/10.1634/theoncologist.2019-0148 https://academic.oup.com/oncolo/article/25/2/e291/6443103 https://academic.oup.com/oncolo/article/25/2/e291/6443103

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)黑色素瘤诊疗指南-2020 [M ] . 北京 : 人民卫生出版社 , 2020 .

Guidelines Working Committee of the Chinese Clinical Oncology Society . Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of melanoma-2020 [M ] . Beijing : People’s Health Publishing House , 2020 .

中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组 . 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0 [J ] . 中华肿瘤杂志 , 2020 , 42 ( 2 ): 81 - 93 .

The Soft Tissue Sarcoma and Malignant Melanoma Research Group of the Sarcoma Professional Committee of the Chinese Anti-Cancer Association . Surgical treatment standards for malignant melanoma of the skin and extremities: Chinese expert consensus 1.0 [J ] . Chin J Oncol , 2020 , 42 ( 2 ): 81 - 93 .

YOU B , BOLZE P A , LOTZ J P , et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase Ⅱ trial [J ] . J Clin Oncol , 2020 , 38 ( 27 ): 3129 - 3137 . DOI: 10.1200/JCO.20.00803 http://doi.org/10.1200/JCO.20.00803 https://ascopubs.org/doi/10.1200/JCO.20.00803 https://ascopubs.org/doi/10.1200/JCO.20.00803

CHENG H , ZONG L , KONG Y , et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 11 ): 1609 - 1617 . DOI: 10.1016/S1470-2045(21)00460-5 http://doi.org/10.1016/S1470-2045(21)00460-5

CHHABRA N , KENNEDY J . A review of cancer immunotherapy toxicity: immune checkpoint inhibitors [J ] . J Med Toxicol , 2021 , 17 ( 4 ): 411 - 424 . DOI: 10.1007/s13181-021-00833-8 http://doi.org/10.1007/s13181-021-00833-8

SULLIVAN R J , WEBER J S . Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies [J ] . Nat Rev Drug Discov , 2022 , 21 ( 7 ): 495 - 508 . DOI: 10.1038/s41573-021-00259-5 http://doi.org/10.1038/s41573-021-00259-5

SANTOMASSO B D , NASTOUPIL L J , ADKINS S , et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 35 ): 3978 - 3992 . DOI: 10.1200/JCO.21.01992 http://doi.org/10.1200/JCO.21.01992 https://ascopubs.org/doi/10.1200/JCO.21.01992 https://ascopubs.org/doi/10.1200/JCO.21.01992

LEE S M , KIM P , YOU J , et al. Role of damage-associated molecular pattern/cell death pathways in vaccine-induced immunity [J ] . Viruses , 2021 , 13 ( 12 ): 2340 . DOI: 10.3390/v13122340 http://doi.org/10.3390/v13122340 https://www.mdpi.com/1999-4915/13/12/2340 https://www.mdpi.com/1999-4915/13/12/2340

DISIS M L , TAYLOR M H , KELLY K , et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial [J ] . JAMA Oncol , 2019 , 5 ( 3 ): 393 - 401 . DOI: 10.1001/jamaoncol.2018.6258 http://doi.org/10.1001/jamaoncol.2018.6258

MINION L E , TEWARI K S . Cervical cancer-state of the science: from angiogenesis blockade to checkpoint inhibition [J ] . Gynecol Oncol , 2018 , 148 ( 3 ): 609 - 621 . DOI: 10.1016/j.ygyno.2018.01.009 http://doi.org/10.1016/j.ygyno.2018.01.009 https://linkinghub.elsevier.com/retrieve/pii/S0090825818300416 https://linkinghub.elsevier.com/retrieve/pii/S0090825818300416

PUZANOV I , DIAB A , ABDALLAH K , et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [J ] . J Immunother Cancer , 2017 , 5 ( 1 ): 95 . DOI: 10.1186/s40425-017-0300-z http://doi.org/10.1186/s40425-017-0300-z

SCHNEIDER B J , LACCHETTI C , BOLLIN K . Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy [J ] . JCO Oncol Pract , 2022 , 18 ( 6 ): 431 - 444 .

赵静 , 苏春霞 . 《CSCO免疫检查点抑制剂相关的毒性管理指南》解读: 对比NCCN免疫治疗相关毒性管理指南 [J ] . 实用肿瘤杂志 , 2020 , 35 ( 1 ): 11 - 15 .

ZHAO J , SU C X . Interpretation of "Toxicity management guidelines for CSCO immunocheckpoint inhibitors": comparing NCCN immunotherapy related toxicity management guidelines [J ] . J Pract Oncol , 2020 , 35 ( 1 ): 11 - 15 .

浏览量

8197

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

MYC通过靶向CD47促进前列腺癌增殖和转移的机制研究

局部晚期头颈部鳞状细胞癌免疫治疗MDT专家共识（2025年版）

转移性结直肠癌三线治疗的研究现状及进展